Clinical Trials Logo

Clinical Trial Summary

Infantile hemangioma (IH) is the most common benign vascular tumor in pediatric population. Oral propranolol is the treatment of choice for complicated hemangiomas. Topical timolol, a non-selective beta-blocker, is an emerging treatment which has been reported to be effective and safe for the treatment of IH, especially for superficial hemangiomas. Investigators hypothesize that treatment with topical timolol in the first two months of life, before the proliferative phase or in early proliferative phase, may prevent from further growing and the need to treat with oral propranolol.


Clinical Trial Description

A multicentric, randomized, double-blind, placebo-controlled, phase II clinical trial to evaluate the efficacy and safety of 0.5% timolol maleate solution for the early treatment of infantile hemangioma.

Patients with less of 60 days of life with focal or segmental hemangiomas, superficial, mixed or abortive will be treated with topical timolol 0.5% twice a day for 24 weeks.

Changes in lesion size, color and thickness will be evaluated from photographs taken at 2,4,8,12,24 and 36 weeks. Vital signs and side effects will be recorded at each visit. Response to treatment will be evaluated by a blinded investigator in a semiquantitative scale (complete resolution, improve, stabilization, worsening). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02731287
Study type Interventional
Source Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact
Status Completed
Phase Phase 2
Start date March 2014
Completion date March 2017

See also
  Status Clinical Trial Phase
Completed NCT01685398 - Topical Timolol for Superficial Infantile Hemangioma Phase 3
Withdrawn NCT00974129 - A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas N/A
Completed NCT00374335 - Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas N/A
Recruiting NCT03331744 - Clinical Characteristics of Infantile Hemangioma
Completed NCT02342275 - Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma Phase 3
Completed NCT00433940 - Immune Suppression Of Infants Treated With Steroids N/A
Completed NCT04065217 - The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial N/A
Terminated NCT01743885 - Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma Phase 3
Terminated NCT00555464 - Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas Phase 2
Completed NCT00394888 - Hemangioma Associated With High Rates of Morbidity N/A
Completed NCT05327309 - Role of Propranolol as Compared to Bleomycin in Management of Hemangioma N/A
Completed NCT02145884 - Topical Timolol Gel for the Treatment of Infantile Hemangiomas Phase 2
Completed NCT04077515 - Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma Phase 4
Recruiting NCT01147601 - Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas Phase 0
Completed NCT01908972 - The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma Phase 4
Completed NCT00540566 - Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Completed NCT00001417 - Direct Injection of Alcohol for the Treatment of Spinal Tumors N/A
Completed NCT00004436 - Randomized Study of Hormonal Regulation of Infantile Hemangioma N/A
Recruiting NCT02496013 - Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB Phase 1
Completed NCT01072045 - Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma Phase 2